Journal Article

Broad Resistance Due to Plasmid-Mediated AmpC β-Lactamases in Clinical Isolates of <i>Escherichia coli</i>

R. Odeh, S. Kelkar, A. M. Hujer, R. A. Bonomo, P. C. Schreckenberger and J. P. Quinn

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 35, issue 2, pages 140-145
Published in print July 2002 | ISSN: 1058-4838
Published online July 2002 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/340742
Broad Resistance Due to Plasmid-Mediated AmpC β-Lactamases in Clinical Isolates of Escherichia coli

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Escherichia coli that produce plasmid-mediated AmpC β-lactamases are rare in the United States. The clinical features associated with infection with these organisms have not been well described. We identified 2 clinical isolates of E. coli that produced the plasmid-mediated AmpC enzyme β-lactamase CMY-2. These organisms were recovered from urine specimens and were resistant to ceftazidime, ceftriaxone, and cefepime. One isolate was resistant to ertapenem but susceptible to imipenem and meropenem; the other was susceptible to imipenem, meropenem, and ertapenem. One of the 2 infected patients did not require specific therapy; the other required imipenem for cure. The presence of the CMY-2 β-lactamase was confirmed by DNA sequencing. Hybridization studies confirmed that the blaCMY-2 gene was on a plasmid in both isolates; in one of them, the probe also hybridized with chromosomal DNA. Infection with plasmid-mediated AmpC β-lactamases in E. coli in the United States may be associated with treatment failure, and these strains may become a serious nosocomial threat.

Journal Article.  3588 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.